Clinical Trials Logo
  1. Home
  2. Sarcoma Uterus
  3. NCT05515575

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

Sarcoma,Soft Tissue Clinical Trial

Official title:
Phase II Study of Niraparib in Soft Tissue Sarcoma Patients With Altered DNA Damage Repair

Clinical Trial Summary

The purpose of this study is to test whether the study drug, niraparib, is effective against unresectable and/or metastatic soft tissue sarcoma with DDR mutations. The researchers will also study whether niraparib is safe and causes few or mild side effects, and whether there are groups of DDR mutations in soft tissue sarcoma cells that respond better to treatment with niraparib.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05515575
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 23, 2022
Completion date August 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT06114004 - Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) Phase 2
Completed NCT01949506 - (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas N/A
Recruiting NCT04595994 - Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma Phase 1
Recruiting NCT05235100 - Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma Phase 2
Completed NCT04991883 - Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities
Recruiting NCT04122872 - GISAR German Interdisciplinary Sarcoma Registry
Recruiting NCT04910126 - Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma Phase 2
Recruiting NCT04219202 - Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05886634 - A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Phase 2
Recruiting NCT05167994 - Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma Phase 2
Recruiting NCT04673942 - A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Phase 2
Recruiting NCT05813327 - Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04172805 - Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma Phase 2
Active, not recruiting NCT04887298 - Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases Phase 1/Phase 2
Active, not recruiting NCT03600649 - Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Phase 1
Recruiting NCT05894018 - Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma Phase 2
Recruiting NCT06263231 - A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) Phase 3
Completed NCT01985295 - Combined Modality Treatment of Sarcomas of the Extremities Phase 1